申请人:Merrell Dow Pharmaceuticals Inc.
公开号:US05106845A1
公开(公告)日:1992-04-21
The present invention is directed to a new class of cyclic guanidines of the formula: ##STR1## in which Q is represented by a substituent selected from the group consisting of (CH.sub.2).sub.n in which n is an integer from 2-10, ##STR2## A is a substituent selected from the group consisting of --NH--(CH.sub.2).sub.m in which m is an integer from 0-5, a piperidino substituent, or a piperazino substituent; both Ar and Ar.sub.1 are each independently represented by a phenyl ring, each of which may be optionally substituted with up to 3 substituents, each selected from the group consisting of halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, and trifluoromethyl; and R is represented by either hydrogen or a C.sub.1-4 alkyl; R.sub.1 is represented by hydrogen or a C.sub.1-4 alkyl; the optional isomers and tautomers thereof; and the pharmaceutically acceptable acid addition salts thereof, and their use as calcium antagonists.
本发明涉及一种新类环状胍二酮,其化学式为:##STR1## 其中Q由选自(CH.sub.2).sub.n的取代基代表,其中n是2-10之间的整数,##STR2## A由选自--NH--(CH.sub.2).sub.m的取代基代表,其中m是0-5之间的整数,一个哌啶基取代基,或一个哌嗪基取代基;Ar和Ar.sub.1各自独立地由苯环代表,每个苯环可以选择性地取代高达3个取代基,每个取代基选自卤素、C.sub.1-4烷基、C.sub.1-4烷氧基和三氟甲基;R由氢或C.sub.1-4烷基代表;R.sub.1由氢或C.sub.1-4烷基代表;以及它们的可选异构体和互变异构体;它们的药学上可接受的酸加盐;以及作为钙拮抗剂的用途。